
	Mr. Paul Estrem, M.B.A., has been a Chief Financial Officer of Melinta Therapeutics, Inc. since December 2, 2013. Mr. Estrem held several senior positions at Baxter International prior to joining Melinta. Mr. Estrem serves as a Member of Board of Managers at Progenitor Cell Therapy, L.L.C. He served as a vice president of integration for Baxter&#39;s Medical Products, where he held a lead role in the $4 billion acquisition of Gambro and oversaw the integration of their products, facilities and 8,000 employees. Mr. Estrem served as Chief Financial Officer of the same Baxter&#39;s Medical Products; Chief Financial Officer and vice president of strategy in Baxter Medication Delivery, a division that later became Baxter&#39;s Medical Products and Chief Financial Officer of Baxter Ltd, a subsidiary based in Tokyo, Japan. He served as the Chief Financial Officer for Baxter&#39;s BioScience Division and the President of BioScience 2002 LLC and has been with Baxter since 1990. Prior to this, he was an head of finance for Baxter&#39;s operations in Japan. Over his 17-year career with Baxter, he has held positions of increasing responsibility including corporate planning, manufacturing finance, and internal audit. Before joining Baxter, he was a Public Accountant at Arthur Andersen and Company for five years. Mr. Estrem is a member of the American Institute for Certified Public Accountants and the Institute of Internal Auditors. He received his Bachelor of Science in accounting from Illinois State University and an MBA from Northwestern University&#39;s Kellogg School of Management.
